Impact of MK886 on eosinophil counts and phenotypic features in toxocariasis

Scandinavian Journal of Immunology

Volumn 65, Issue 4, 2007, Pages 344-352

  Anibal, F F ^a   Rogerio, A P ^a   Malheiro, A ^a   Machado, E R ^a   Martins Filho, O A ^b   Andrade, M C ^b   Soares, E G ^a   Medeiros, A I ^a   Faccioli, L H ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b INSTITUTO OSWALDO CRUZ   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

3 [3 TERT BUTYLTHIO 1 (4 CHLOROBENZYL) 5 ISOPROPYL 2 INDOLYL] 2,2 DIMETHYLPROPIONIC ACID; BETA1 INTEGRIN; BETA2 INTEGRIN; CD11B ANTIGEN; LEUKOTRIENE; VERY LATE ACTIVATION ANTIGEN 4;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL MIGRATION; CONTROLLED STUDY; EOSINOPHIL COUNT; EOSINOPHILIA; FEMALE; IMMUNOPHENOTYPING; INFLAMMATION; INOCULATION; LUNG LAVAGE; MOUSE; NONHUMAN; PERITONEAL CAVITY; PRIORITY JOURNAL; TOXOCARA CANIS; TOXOCARIASIS; UPREGULATION; VISCERAL LARVA MIGRANS SYNDROME;

ANIMALS; BRONCHOALVEOLAR LAVAGE FLUID; CELL MOVEMENT; EOSINOPHILIA; EOSINOPHILS; FEMALE; FLOW CYTOMETRY; INDOLES; INTEGRIN ALPHA4BETA1; LIPOXYGENASE INHIBITORS; MACROPHAGE-1 ANTIGEN; MICE; MICE, INBRED BALB C; PHENOTYPE; TOXOCARIASIS;

EID: 33947599475     PISSN: 03009475     EISSN: 13653083     Source Type: Journal    
DOI: 10.1111/j.1365-3083.2007.01911.x     Document Type: Article

References (48)

1. Beaver P, Snyder H, Carrera G et al. Chronic eosinophilia due to visceral larvae migrans. Pediatrics 1952;9:7-19.
2. Kayes SG, Oaks JA. Development of the granulomatous response in murine toxocariasis. Initial events. Am J Pathol 1978;93:277-94.
3. Turner KJ, Feddema L, Quinn EH. Non-specific potentiation of IgE by parasitic infections in man. Int Arch Allergy Appl Immunol 1979;58:232-6.
4. Taylor MR, Keane CT, O'connor P et al. The expanded spectrum of toxocaral disease. Lancet 1988;26:692-5.
5. Buijs J, Lkhorst WH, Nijkamp FP. Toxocara canis-induced murine pulmonary inflammation: analysis of cells and proteins in lung tissue and bronchoalveolar lavage fluid. Parasite Immunol 1994;16:1-9.
6. Faccioli LH, Mokva VF, Silva CL et al. IL-5 drives eosinophils from bone marrow to blood and tissues in a visceral larva migrans syndrome. Mediators Inflamm 1996;5:24-31.
7. Kay AB, Moqbel R, Durham SR et al. Leucocyte activation initiated by IgE-dependent mechanisms in relation to helminthic parasitic disease and clinical models of asthma. Int Arch Allergy Appl Immunol 1985;77:69-72.
8. Pinelli E, Dormans J, Fonville M et al. A comparative study of toxocariasis and allergic asthma in murine models. Helminthology 2001;75:137-40.
9. Samuelsson B. Leukotrienes: mediators of immediate hypersensitivity reactions and inflammation. Science 1983;220:568-75.
10. O'Byrne PM. Leukotrienes, airway hyperresponsiveness, and asthma. Ann NY Acad Sci 1988;524:282-8.
11. Drazen JM, Austen KF, Lewis RA et al. Comparative airway and vascular activity of leukotriene C-1 and D in vivo and in vitro. Proc Natl Acad Sci 1980;77:4345-58.
12. 4, increase the release of mucus from human airways in vitro. Am Rev Respir Dis 1982;126:449-51.
13. Hanna CJ, Bach MK, Pare PD et al. Slow reacting substances (leukotrienes) contract human airway and pulmonary vascular smooth muscle in vitro. Nature 1981;290:343-4.
14. Spada CS, Woodward DF, Hawley SB et al. Leukotrienes cause eosinophil emigration into conjunctival tissue. Prostaglandins 1986;31:795-809.
15. 111In-eosinophils induced by inflammation mediators, in vivo. Immunology 1991;73:222-7.
16. Henderson WR Jr. The role of leukotrienes in inflammation. Ann Intern Med 1994;121:684-97.
17. Gillard J, Ford-Hutchinson AW, Chan C et al. L-663,536 (MK886) (3-[1-(4-chlorobenzyl)-3-t-butyl-thio-5-isopropylindol-2-yl]-2, 2-imethylpropanoic acid), a novel, orally active leukotrienes biosynthesis inhibitor. Can J Physiol Pharmacol 1989;67:456-564.
18. Ford-Hutchinson AW. FLAP: a novel drug target for inhibiting the synthesis of leukotrienes. Trends Pharmacol Sci 1991;12:68-70.
19. Puustinen T, Scheffer MM, Samuelsson B. Regulation of the human leukocyte 5-lipoxygenase: stimulation by micromolar Ca2+ levels and phosphatidylcholine vesicles. Biochim Biophys Acta 1988;960:261-7.
20. Medeiros AI, Silva CL, Malheiro A et al. Leukotrienes are involved in leukocyte recruitment induced by live Histoplasma capsulatum or by the β-glucan present in their cell wall. Br J Pharmacol 1999;128:1529-37.
21. Medeiros AI, Sá-Nunes A, Soares EG et al. Blockade of endogenous leukotrienes exacerbates pulmonary histoplasmosis. Infect Immun 2004;72:1637-44.
22. Dobrina A, Menegazzi R, Carlos TM et al. Mechanisms of eosinophil adherence to cultured vascular endothelial cells. Eosinophils bind to cytokine-induce ligant vascular cell adhesion molecule-1 via the very late activation antigen-4 integrin receptor. J Clin Invest 1991;88:20-6.
23. Walsh GM, Mermod JJ, Hartnell A et al. Human eosinophil, but not neutrophil, adherence to IL-1-stimulated human umbilical vascular endothelial cells is a4b1 (very late antigen-4) dependent. J Immunol 1991;146:3419-23.
24. Schleimer RP, Sterbinsky SA, Kaiser J et al. IL-4 induces adherence of human eosinophils and basophils but not neutrophils to endothelium. Association with expression of VCAM-1. J Immunol 1992;148:1086-92.
25. Sriramarao P, Ulcrich HVA, Butcher EC et al. L-selectin and very late antigen-4 promote eosinophil rolling at physiological shear rates in vivo. J Immunol 1994;153:4238-46.
26. Jia GQ, Gonzalo JA, Hidalgo A et al. Selective eosinophil transendothelial migration triggered by eotaxin via modulation of Mac-1/ICAM-1 and VLA-4/VCAM-1 interactions. Int Immunol 1999;11:1-10.
27. Komatsu H, Amano M, Yamaguchi S et al. Inhibition of activation of human peripheral blood eosinophils by Y-24180, an antagonist to platelet-activating factor receptor. Life Sci 1999;65:171-6.
28. 4 upregulates eosinophil adhesion via the cysteinyl leukotriene 1 receptor. J Allergy Clin Immunol 2002;109:676-80.
29. Olson LJ, Schutz CV. Nematode induced hypersensibility reactions in guinea pig: onset of eosinophilia and positive Schultz-Dale reactions following graded infection with Toxocara canis. Ann NY Acad Sci 1963;113:440-55.
30. Braccioni F, Dorman SC, O'Byrne PM et al. The effect of cysteinyl leukotrienes on growth of eosinophil progenitors from peripheral blood and bone marrow of atopic subjects. J Allergy Clin Immunol 2002;110:96-101.
31. Kellaway CH, Trethewie ER. The liberation of a slow-reacting smooth muscle-stimulating substance in anaphylaxis. Q J Exp Physiol 1940;30:121-45.
32. Brocklehurst WE. The release of histamine and formation of a slow-reacting substance (SRS-A) during anaphylactic shock. J Physiol 1960;151:416-35.
33. Lee TH, Arm J. Leukotrienes. Allergy Proc 1991;12:139-42.
34. Chaudhuri RN, Saha TK. Tropical eosinophilia. Experiments with Toxocara canis. Lancet 1959;2:493-4.
35. Rogerio AP, Sá-Nunes A, Albuquerque DA et al. Lafoensia pacari extract inhibits IL-5 production in toxocariasis. Parasite Immunol 2003;25:393-400.
36. Coffman RL, Seymour BWP, Judak S et al. Antibody to interleukin-5 inhibits helminth-induced eosinophilia in mice. Science 1989;245:308-10.
37. Sher A, Coffman RL, Hieny S et al. Ablation of eosinophil and IgE responses with anti-IL-5 or anti-IL-4 antibodies fails to affect immunity against Schistosoma mansoni in the mouse. J Immunol 1990;145:3911-6.
38. Parsons JC, Coffman RL, Grieve RB. Antibody to interleukin-5 prevents blood and tissue eosinophilia but not liver trapping in murine larval toxocariasis. Parasite Immunol 1993;15:501-8.
39. Collins PD, Marleau S, Griffiths-Johnson DA et al. Cooperation between interleukin-5 and the chemokine eotaxin to induce eosinophil accumulation in vivo. J Exp Med 1995;182:1169-74.
40. Sá-Nunes A, Medeiros AI, Faccioli LH. Interleukin-5 mediates peritoneal eosinophilia induced by the F1 cell wall fraction of Histoplasma capsulatum. Braz J Med Biol Res 2004;37:343-6.
41. Fischer E, Capron M, Prin L et al. Human eosinophils express CR1 and CR3 complement receptors for cleavage fragments of C3. Cell Immunol 1986;97:297-306.
42. Tomioka K, MacGlashan DW Jr, Lichtenstein LM et al. GM-CSF regulates human eosinophil responses to F-Met peptide and platelet activating factor. J Immunol 1993;151:4989-97.
43. Lundahl J, Hallden G, Hed J. Differences in intracellular pool and receptor-dependent mobilization of the adhesion-promoting glycoprotein Mac-1 between eosinophils and neutrophils. J Leukoc Biol 1993;53:336-41.
44. Anwar AR, Moqbel R, Walsh GM et al. Adhesion to fibronectin prolongs eosinophil survival. J Exp Med 1993;177:839-43.
45. Anwar AR, Walsh GM, Cromwell O et al. Adhesion to fibronectin primes eosinophils via alpha 4 beta 1 (VLA-4). Immunology 1994;82:222-8.
46. Bochner BS, Luscinskas FW, Gimbrone MA Jr et al. Adhesion of human basophils, eosinophils, and neutrophils to IL-1-activated human vascular endothelial cells: contributions of endothelial cell adhesion molecules. J Exp Med 1991;173:1553-7.
47. Weller PF, Rand TH, Goelz SE et al. Human eosinophil adherence to vascular endothelium mediated by binding to vascular cell adhesion molecule 1 and endothelial leukocyte adhesion molecule 1. Proc Natl Acad Sci USA 1991;88:7430-3.
48. Shahabuddin S, Ponath P, Schleimer RP. Migration of eosinophils across endothelial cell monolayers: interactions among IL-5, endothelial-activating cytokines, and C-C chemokines. J Immunol 2000;164:3847-53.